Valuation: Compass Therapeutics, Inc.

Market Cap 373M 328M 305M 280M 526M 35.75B 533M 3.63B 1.42B 17.65B 1.4B 1.37B 61.01B P/E 2026 *
-4.75x
P/E 2027 * -4.45x
Enterprise Value 223M 196M 182M 167M 314M 21.36B 319M 2.17B 846M 10.55B 836M 818M 36.46B EV / Sales 2026 *
-108x
EV / Sales 2027 * 9.53x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day+0.48%
1 week+1.46%
Current month-5.02%
3 months-58.65%
6 months-66.40%
Current year-61.27%
1 week 1.99
Extreme 1.99
2.22
1 month 1.99
Extreme 1.99
2.36
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 28/05/2024
Director of Finance/CFO 54 09/12/2024
Chief Tech/Sci/R&D Officer 50 01/01/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2014
Director/Board Member 64 01/01/2015
Chairman 61 01/01/2015
Date Insider Type Main position Quantity % Market Cap.
29/4/26 Buy

Controller/Auditor

15,000 0.0083%
29/4/26 Buy

General Counsel

25,000 0.0139%
8/2/26 Tax

Chief Executive Officer

36,687 0.0206%
Change 5-day change 1-year change 3-year change Capi.($)
+0.48%+1.46%-34.59%-18.75% 373M
-1.82%+5.03%+56.71%+66.69% 57.28B
-0.27%+5.74%+40.26%+80.17% 54.99B
-2.05%-3.31%+0.75%+414.39% 23.18B
+1.97%-0.43%-21.00%-13.67% 22.59B
-1.13%+4.54%+22.73%-8.06% 20.46B
+1.57%+2.09%+28.01%-27.56% 17.56B
-0.10%+5.57%+38.63%+565.16% 15.67B
+5.29%0.00%+185.09%+332.66% 14.46B
+0.79%-0.20%+22.39%+181.58% 13.92B
Average +0.55%+1.55%+33.90%+157.26% 24.05B
Weighted average by Cap. -0.06%+1.93%+39.68%+137.48%

Financials

2026 *2027 *
Net sales -2.06M -1.81M -1.68M -1.55M -2.9M -197M -2.94M -20.01M -7.82M -97.41M -7.72M -7.56M -337M 25.27M 22.21M 20.68M 18.99M 35.66M 2.42B 36.13M 246M 96M 1.2B 94.86M 92.81M 4.14B
Net income -82.44M -72.47M -67.46M -61.95M -116M -7.91B -118M -802M -313M -3.9B -309M -303M -13.49B -89.57M -78.74M -73.3M -67.31M -126M -8.59B -128M -871M -340M -4.24B -336M -329M -14.66B
Net Debt -150M -132M -123M -113M -212M -14.38B -214M -1.46B -570M -7.1B -563M -551M -24.55B -132M -116M -108M -99.2M -186M -12.66B -189M -1.28B -501M -6.25B -496M -485M -21.6B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
28/07/26 US$2.080 +0.48% 3,400,976
24/07/26 US$2.070 -2.36% 1,589,937
23/07/26 US$2.120 +3.92% 2,266,567
22/07/26 US$2.040 -2.86% 1,771,804
21/07/26 US$2.100 +3.96% 1,620,718
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.070USD
Average target price
8.500USD
Spread / Average Target
+310.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock